These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 20728382

  • 1. BAX/BCL-XL gene expression ratio inversely correlates with disease progression in chronic myeloid leukemia.
    Gonzalez MS, De Brasi CD, Bianchini M, Gargallo P, Moiraghi B, Bengió R, Larripa IB.
    Blood Cells Mol Dis; 2010 Oct 15; 45(3):192-6. PubMed ID: 20728382
    [Abstract] [Full Text] [Related]

  • 2. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
    Gutiérrez-Castellanos S, Cruz M, Rabelo L, Godínez R, Reyes-Maldonado E, Riebeling-Navarro C.
    Eur J Haematol; 2004 Apr 15; 72(4):231-8. PubMed ID: 15089759
    [Abstract] [Full Text] [Related]

  • 3. Expression of programmed cell death proteins in patients with chronic myeloid leukemia.
    Strnad M, Brajuskovic G, Strelic N, Todoric-Zivanovic B, Stamatovic D, Tatomirovic Z, Magic Z.
    J BUON; 2008 Apr 15; 13(3):403-8. PubMed ID: 18979557
    [Abstract] [Full Text] [Related]

  • 4. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C, Bianchini M, Bengió R, Larripa I.
    Blood Cells Mol Dis; 2014 Apr 15; 52(2-3):121-5. PubMed ID: 24091144
    [Abstract] [Full Text] [Related]

  • 5. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
    Liu XL, Zhou SY, Du QF, Zheng WY, Zhang S, Song LL, Xu B, Liu QF, Meng FY.
    Ai Zheng; 2004 Apr 15; 23(4):421-5. PubMed ID: 15087031
    [Abstract] [Full Text] [Related]

  • 6. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
    Wang S, Chai YB, Liu F, Zhang XY, Jia W, Xie X, Yu WQ, Shang ZC, Jin BQ, Sun BZ.
    Zhonghua Yi Xue Za Zhi; 2005 Jan 19; 85(3):198-202. PubMed ID: 15854468
    [Abstract] [Full Text] [Related]

  • 7. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells.
    Cheong JW, Chong SY, Kim JY, Eom JI, Jeung HK, Maeng HY, Lee ST, Min YH.
    Clin Cancer Res; 2003 Oct 15; 9(13):5018-27. PubMed ID: 14581377
    [Abstract] [Full Text] [Related]

  • 8. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, Pattacini L, Goldman JM, Melo JV.
    Cancer Res; 2005 Oct 01; 65(19):8912-9. PubMed ID: 16204063
    [Abstract] [Full Text] [Related]

  • 9. Early down-regulation of Bcl-xL expression during megakaryocytic differentiation of thrombopoietin-induced CD34+ bone marrow cells in essential thrombocythemia.
    Zhang L, Zhao H, Sun A, Lu S, Liu B, Tang F, Feng Y, Zhao L, Yang R, Han ZC.
    Haematologica; 2004 Oct 01; 89(10):1199-206. PubMed ID: 15477204
    [Abstract] [Full Text] [Related]

  • 10. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
    Koh Y, Kim I, Yoon SS, Kim BK, Kim DY, Lee JH, Lee KH, Park E, Kim HJ, Sohn SK, Joo YD, Kim SJ, Chung J, Shin HJ, Kim SH, Kim CS, Song HS, Kim MK, Hyun MS, Ahn JS, Jung CW, Park S, Korean Society of Hematology CML working party.
    Ann Hematol; 2010 Jul 01; 89(7):725-31. PubMed ID: 20179930
    [Abstract] [Full Text] [Related]

  • 11. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu, Turkina AG, Misiurin AV, Aksenova EV, Domracheva EV, Zakharova AV, Khoroshko ND.
    Ter Arkh; 2007 Jul 01; 79(4):49-53. PubMed ID: 17564019
    [Abstract] [Full Text] [Related]

  • 12. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
    Zhu XZ, Yu YZ, Fang YM, Liang Y, Lü QH, Xu RZ.
    Zhonghua Yi Xue Za Zhi; 2005 Jul 20; 85(27):1903-6. PubMed ID: 16255985
    [Abstract] [Full Text] [Related]

  • 13. [Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].
    Xing W, Gu BW, Zhu YM, Jiang CL, Zhao RH, Wang AH, Sun HP, Li JM, Shen ZX, Chen Z, Chen SJ.
    Zhonghua Yi Xue Za Zhi; 2005 Feb 23; 85(7):453-7. PubMed ID: 15854550
    [Abstract] [Full Text] [Related]

  • 14. [Molecular analysis of transformation into blast crisis in chronic myelogenous leukemia].
    Okabe M.
    Hokkaido Igaku Zasshi; 1993 Mar 23; 68(2):237-50. PubMed ID: 8509066
    [Abstract] [Full Text] [Related]

  • 15. [Cytogenetic response as a marker of efficacy of chronic myeloid leukemia therapy with a BCR-ABL thyrosine kinase inhibitor glivek].
    Turkina AG, Kruglov SS, Druzhkova GA, Domracheva EV, Zakharova AV, Vinogradova OIu, Sysoeva EP, Diachenko LV, Chelysheva EIu, Zakharova ES, Abakumov EM, Kolosheĭnova TI, Kolosova LIu, Ivanova TV, Zhuravlev VS, Nemchenko IS, Zingerman BV, Kurova ES, Triputen' NZ, Loriia SS, Kovaleva LG, Khoroshko ND.
    Ter Arkh; 2005 Mar 23; 77(7):42-7. PubMed ID: 16116908
    [Abstract] [Full Text] [Related]

  • 16. Enforced expression of Bcl-XS induces differentiation and sensitizes chronic myelogenous leukemia-blast crisis K562 cells to 1-beta-D-arabinofuranosylcytosine-mediated differentiation and apoptosis.
    Ray S, Bullock G, Nuñez G, Tang C, Ibrado AM, Huang Y, Bhalla K.
    Cell Growth Differ; 1996 Dec 23; 7(12):1617-23. PubMed ID: 8959329
    [Abstract] [Full Text] [Related]

  • 17. [Study on mismatch repair genes of chronic myeloid leukemia].
    Luo J, Peng ZG, Chen Y, Lai YR, Lu YY, Song SJ.
    Zhonghua Xue Ye Xue Za Zhi; 2006 Feb 23; 27(2):103-6. PubMed ID: 16732964
    [Abstract] [Full Text] [Related]

  • 18. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL.
    Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON, Green DR.
    Oncogene; 1998 Mar 23; 16(11):1383-90. PubMed ID: 9525737
    [Abstract] [Full Text] [Related]

  • 19. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A.
    Cancer; 2005 Apr 15; 103(8):1659-69. PubMed ID: 15747376
    [Abstract] [Full Text] [Related]

  • 20. Glucosamine sulfate-induced apoptosis in chronic myelogenous leukemia K562 cells is associated with translocation of cathepsin D and downregulation of Bcl-xL.
    Wang Z, Liang R, Huang GS, Piao Y, Zhang YQ, Wang AQ, Dong BX, Feng JL, Yang GR, Guo Y.
    Apoptosis; 2006 Oct 15; 11(10):1851-60. PubMed ID: 16850161
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.